NEW HAVEN, Conn., Jan. 30, 2025 /PRNewswire/ -- (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of pat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback